Fortress Biotech, Inc.

FBIO Healthcare Biotechnology

Fortress Biotech, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $63.3 million, up 9.69% from fiscal 2024. In the quarter to June 2026, revenue grew 14.0%, EPS fell 116.0%, free cash flow fell 115.4% and total debt fell 35.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

1.87 0.04 −2.09%
Market cap
$63.7M
P/E
0.6×
Fwd P/E
1.1×
Dividend yield
—
F-score
5/9
Altman Z
−5.47
Beneish M
−0.01
Dividend safety
20/100
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
6 7 5 3

+8 more TTM periods

ROE
84.91% 101.51% (6.22%) (20.35%)
ROA
43.38% 44.56% (1.14%) (3.46%)
ROIC
(41.34%) 0.00% (124.61%) (209.25%)
Return on Tangible Assets
55.60% 61.28% (2.46%) (7.96%)
Average Days of Receivables
195.93 140.72 172.75 106.18
Free Cash Flow per Share
3.96 5.00 (2.32) (2.39)
Free Cash Flow
125.84 157.64 (64.61) (65.04)
Other line items

Show all line items

Columns are period end dates